DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Clinical trials for DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT trials appear
Sign up with your email to follow new studies for DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Sound waves open Brain's shield to attack deadly childhood tumors
Disease control Recruiting nowThis early-stage study tests whether a non-invasive ultrasound technique can temporarily open the blood-brain barrier in children with progressive diffuse midline glioma (DMG), a rare and aggressive brain tumor. The goal is to let more of the oral chemotherapy drug etoposide reac…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: Columbia University • Aim: Disease control
Last updated May 16, 2026 22:30 UTC
-
Promising drug cocktail targets tough brain cancers in kids
Disease control Recruiting nowThis study tests two drug combinations given after radiation for children and young adults with aggressive brain tumors (high-grade glioma or DIPG). One group receives ribociclib plus everolimus; another gets ribociclib plus temozolomide. The goal is to see if these combinations …
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated May 16, 2026 22:29 UTC
-
New hope for kids with rare brain tumors: adaptive trial tests drug cocktails
Disease control Recruiting nowThis study tests whether combining the drug ONC201 with other new agents can help children and young adults with diffuse midline gliomas (DMGs), including DIPG. The trial uses an adaptive design, meaning new drug combinations can be added as research evolves. About 360 participan…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New pill takes on brain tumors: first human trial begins
Disease control Recruiting nowThis early-stage trial tests an oral drug called ONC206 in adults with brain tumors that have come back. The main goal is to find the safest dose and understand side effects. About 102 participants will receive the drug weekly or multiple days per week.
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope for kids with DIPG: major trial launches
Disease control Recruiting nowThis phase 3 trial tests whether the drug ONC201 works better than everolimus for children with diffuse intrinsic pontine glioma (DIPG), a rare and aggressive brain tumor. About 433 participants will be randomly assigned to one of the two drugs, and if their disease gets worse, t…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Engineered immune cells injected directly into brain to fight childhood tumors
Disease control Recruiting nowThis early-stage trial tests a new treatment for children and young adults (up to age 21) with certain brain tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack a p…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New vaccine combo aims to fight deadly childhood brain tumors
Disease control Recruiting nowThis early-phase trial tests a new vaccine (rHSC-DIPGVax) combined with two immunotherapy drugs (BALSTILIMAB and ZALIFRELIMAB) in children with diffuse intrinsic pontine glioma (DIPG) or diffuse midline glioma (DMG). The vaccine is designed to help the immune system recognize and…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago • Aim: Disease control
Last updated Apr 29, 2026 15:02 UTC
-
Could two weeks of radiation be as good as six for brainstem glioma?
Symptom relief Recruiting nowThis study is for people with a rare, aggressive brain tumor called diffuse midline glioma. Instead of the usual 6 weeks of daily radiation, researchers are testing a 2-week course. The goal is to see if the shorter treatment keeps the tumor from growing as long while also improv…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated May 11, 2026 20:40 UTC
-
Brain tumor genetics could unlock personalized treatments for kids
Knowledge-focused Recruiting nowThis study is for children, teens, and young adults (ages 1 to 39) newly diagnosed with a high-grade glioma, a serious type of brain tumor. Researchers will analyze the tumor's genetic makeup to see if it matches a specific treatment plan in a future study. The goal is to learn m…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Sponsor: Nationwide Children's Hospital • Aim: Knowledge-focused
Last updated May 16, 2026 22:27 UTC
-
Global effort to unlock secrets of rare childhood brain tumors
Knowledge-focused Recruiting nowThis study creates a worldwide database of medical information and tumor samples from people with DIPG or DMG, rare and aggressive brain tumors. Researchers aim to learn how these tumors work at a molecular level to help design better treatments in the future. Anyone diagnosed wi…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated May 15, 2026 11:53 UTC
-
Brain tumor study aims to sharpen diagnosis and treatment
Knowledge-focused Recruiting nowThis study looks at how the latest brain tumor classification system (from 2021) helps doctors better understand and treat different types of brain tumors. Researchers will collect data from 1,650 patients to see if the new system groups patients more accurately and to create tre…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Knowledge-focused
Last updated May 06, 2026 16:03 UTC